Merck's (MRK +0.3%) insomnia drug suvorexant maintained its effectiveness for 12 months in a...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck's (MRK +0.3%) insomnia drug suvorexant maintained its effectiveness for 12 months in a late-stage study. Suvorexant is one of 6 treatments that Merck will seek FDA approval for in 2012 and 2013 as it looks to compensate for the upcoming loss of patent protection for its blockbuster asthma treatment Singulair.